导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -3.66% | 3262/4773 |
| 近一周 | -1.30% | 1987/5465 |
| 近一月 | -1.19% | 1057/5421 |
| 近一季 | -0.44% | 1063/5231 |
| 近半年 | -1.40% | 1772/4920 |
| 近一年 | -0.56% | 2851/4394 |
| 近两年 | 33.48% | 2151/2954 |
| 近三年 | 21.03% | 1448/2253 |
| 成立以来 | 51.16% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.30% 4087/4961 |
6.27% 2841/5312 |
- - |
- - |
| 2025 | 14.60% 2598/4813 |
-0.61% 2324/3635 |
2.62% 1459/4076 |
10.32% 3303/4524 |
1.84% 1193/4813 |
| 2024 | 17.65% 663/3463 |
3.33% 591/2808 |
-0.16% 696/3014 |
16.02% 1563/3129 |
-1.71% 1801/3463 |
| 2023 | -8.73% 1053/2656 |
0.83% 1689/2280 |
-4.54% 1198/2385 |
1.52% 302/2515 |
-6.60% 1841/2655 |
| 2022 | -15.96% 444/2207 |
-10.79% 423/1919 |
6.51% 680/2016 |
-12.59% 735/2113 |
1.17% 1356/2208 |
| 2021 | -6.17% 999/1822 |
-2.11% 583/1255 |
0.54% 1094/1330 |
-6.57% 958/1466 |
2.05% 716/1822 |
| 2020 | 27.39% 584/1250 |
-9.59% 693/1028 |
11.41% 734/1067 |
12.94% 352/1164 |
11.98% 505/1184 |
| 2019 | 26.18% 582/1092 |
12.69% 705/739 |
3.77% 44/788 |
1.66% 379/850 |
6.14% 653/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 建信上证50ETF发起联接A VS. 长安沪深300非周期A(740101) |